Efficacy and Safety of NA-1 in subjects with Acute Ischemic Stroke
Research type
Research Study
Full title
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects with Acute Ischemic Stroke Undergoing Endovascular Thrombectomy (ESCAPE-NA1 Trial)
IRAS ID
216149
Contact name
Paul Burns
Contact email
Sponsor organisation
NoNO Inc.
Eudract number
2016-001826-33
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 4 months, 1 days
Research summary
NA-1 is an investigational drug being developed as an emergency medication aimed at preventing damage to brain cells during a stroke if it is given soon after symptom onset. “Investigational” means that the drug hasn't been licensed to use in the market. The purpose of this study is to test if a single dose of NA-1 can reduce neurological disability in people who have had a stroke and who are selected for endovascular revascularisation.
NA-1 acts by blocking a protein in the brain responsible for cell damage during a stroke. The safety of NA-1 has been tested previously in healthy people and in patients having strokes in hospitals when undergoing brain aneurysm repair procedures.
REC name
HSC REC B
REC reference
17/NI/0108
Date of REC Opinion
19 Jul 2017
REC opinion
Further Information Favourable Opinion